Trial Profile
Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension (BETTER-HTN).
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs ACE inhibitors; Alpha adrenergic receptor agonists; Angiotensin receptor antagonists; Beta-adrenergic receptor antagonists; Calcium channel antagonists; Dihydropyridines; Loop diuretics; Potassium-sparing diuretics; Thiazide diuretics; Vasodilators
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms BETTER-HTN
- 17 Jun 2009 New trial record